Show simple item record

dc.contributor.authorYu, EYen
dc.contributor.authorGillessen, Silkeen
dc.contributor.authorMottet, Nen
dc.date.accessioned2018-12-05T10:35:51Z
dc.date.available2018-12-05T10:35:51Z
dc.date.issued2018en
dc.identifier.citationYu EY, Gillessen S, Mottet N. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. European Urology Focus [Internet]. 2018 Oct.en
dc.identifier.pmid30287277en
dc.identifier.doi10.1016/j.euf.2018.09.015en
dc.identifier.urihttp://hdl.handle.net/10541/621372
dc.description.abstractClinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.euf.2018.09.015en
dc.titleWhat Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendationsen
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA;en
dc.identifier.journalEur Urol Focusen
dc.description.noteen]


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record